Affordable Access

Topical Fluoxetine as a Novel Therapeutic That Improves Wound Healing in Diabetic Mice.

Authors
  • Nguyen, Chuong Minh
  • Tartar, Danielle Marie
  • Bagood, Michelle Dawn
  • So, Michelle
  • Nguyen, Alan Vu
  • Gallegos, Anthony
  • Fregoso, Daniel
  • Serrano, Jorge
  • Nguyen, Duc
  • Degovics, Doniz
  • Adams, Andrew
  • Harouni, Benjamin
  • Fuentes, Jaime Joel
  • Gareau, Melanie G
  • Crawford, Robert William
  • Soulika, Athena M
  • Isseroff, Roslyn Rivkah
Publication Date
Jul 01, 2019
Source
eScholarship - University of California
Keywords
License
Unknown
External links

Abstract

Diabetic foot ulcers represent a significant source of morbidity in the U.S., with rapidly escalating costs to the health care system. Multiple pathophysiological disturbances converge to result in delayed epithelialization and persistent inflammation. Serotonin (5-hydroxytryptamine [5-HT]) and the selective serotonin reuptake inhibitor fluoxetine (FLX) have both been shown to have immunomodulatory effects. Here we extend their utility as a therapeutic alternative for nonhealing diabetic wounds by demonstrating their ability to interact with multiple pathways involved in wound healing. We show that topically applied FLX improves cutaneous wound healing in vivo. Mechanistically, we demonstrate that FLX not only increases keratinocyte migration but also shifts the local immune milieu toward a less inflammatory phenotype in vivo without altering behavior. By targeting the serotonin pathway in wound healing, we demonstrate the potential of repurposing FLX as a safe topical for the challenging clinical problem of diabetic wounds.

Report this publication

Statistics

Seen <100 times